MABVAX THERAPEUTICS HLDGS INC
MBVX
MBVX was delisted on the 10th of July, 2018.
14 hedge funds and large institutions have $1.13M invested in MABVAX THERAPEUTICS HLDGS INC in 2018 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 0 closing their positions.
27% more funds holding
Funds holding: 11 → 14 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
34% less capital invested
Capital invested by funds: $1.72M → $1.13M (-$586K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$96.2K |
| 2 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$63.3K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$34.7K |
| 4 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$19.8K |
| 5 |
VF
Virtu Financial
New York
|
+$16.2K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Cambridge Investment Research Advisors
Fairfield,
Iowa
| $876K | +$63.3K | +49,967 | +5% |
|
2
Vanguard Group
Malvern,
Pennsylvania
| $108K | – | – | – |
|
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $65K | +$96.2K | +75,904 | New |
|
|
4
Commonwealth Equity Services
Waltham,
Massachusetts
| $24K | +$19.8K | +15,662 | +128% |
|
|
5
Citadel Advisors
Miami,
Florida
| $23K | +$34.7K | +27,385 | New |
|
|
VF
6
Virtu Financial
New York
| $11K | +$16.2K | +12,783 | New |
|
7
UBS Group
Zurich,
Switzerland
| $10K | +$13K | +10,237 | +620% |
|
|
BCM
8
Biomark Capital Management
Greenwich,
Connecticut
| $8K | – | – | – |
|
9
Bank of America
Charlotte,
North Carolina
| $6K | +$422 | +333 | +5% |
|
10
Royal Bank of Canada
Toronto,
Ontario, Canada
| $3K | – | – | – |
|
MBVX Hedge Fund Activity: Q2 2018 in Review
14 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in MABVAX THERAPEUTICS HLDGS INC (MBVX) for Q2 2018, worth a combined $1.13M — down 34% from $1.72M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new MBVX positions and 0 closed out — a net gain of 3 holders — while 4 added to existing stakes and 0 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $96.2K.
- 14 institutional investors held MABVAX THERAPEUTICS HLDGS INC (MBVX) as of Q2 2018, up from 11 in Q1 2018.
- Funds reported $1.13M of MABVAX THERAPEUTICS HLDGS INC stock for Q2 2018, down 34% quarter-over-quarter.
- 3 funds opened new MABVAX THERAPEUTICS HLDGS INC positions in Q2 2018 and 0 closed out, a net change of +3 holders.
- The largest MABVAX THERAPEUTICS HLDGS INC buyer in Q2 2018 was Susquehanna International Group, an estimated $96.2K added.
Based on aggregated 13F filings for Q2 2018.